Cyagen: Cyagen and Neurophth Collaborate in the Development of AAV Gene Therapy for Ophthalmic Conditions

A strategic partnership between Neurophth Thearapeutics, Inc. and Cyagen develop the next-generation adeno-associated virus (AAV) gene therapy vectors for specific ophthalmic genetic conditions. The official agreement states that Cyagen will use its patented AI-powered platform to uncover original AAV vectors with enhanced tissue targeting capability, specificity, and productivity. Cyagen and Neurophth will assess the functional [...]